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Summary
The gene responsible for the pathogenesis of cystic fi-
brosis has been known for over 15 years (1, 2). Cystic
fibrosis is the most common autosomal recessive dis-
ease in the european population (3). More that 1500 mu-
tations and a large number of polymorphisms have
been identified so far from 1989. In the past 10 years we
examined in our centre 25393 fetuses. The exams
brought to the identification 0f 922 heterozygous and 9
homozygous for the mutation. The frequency of het-
erozygous in the examined sample was 1/27,5 while
that of the affected was 1/2821. We carried out the ex-
amination of the most frequent mutations which en-
able, according to the literature data, the identification
of almost 80% of the affected alleles (4-8).
Introduction
The cystic fibrosis gene encompasses more than
250.000 bp and contains 27 exons. The The cystic fibro-
sis transmembrane conductance regulator (CFTR) gene
is located on chromosome 7 and encodes for an ion
channel protein of 1.480 aminoacids which mediates
chloride conductance across biological membranes. Not
all of the sequence variations or mutations determine
the clinical manifestation of the disease, while a certain
number of nucleotidic changes are associated with atyp-
ical forms that in many cases are not defined in terms of
their pathogenetic role. 
The frequency of mutations is variable in terms of geo-
graphical distribution of the populations and several mu-
tations have been found to be more frequent in some
populations compared to others. The most frequently
observed mutation is the ΔF508, which is more common
in the north of Europe (4, 5), and shows in Italy an esti-
mated frequency of around 51% (5-11). 
The first level genetic analysis allows a very quick de-
tection of the most frequent mutations in the population
through the use of techniques which are based upon
commercially available kits. In Italy the commercial kits
allow at present time the identification of more than thir-
ty mutations with a detection rate estimated at almost
80% (4-8). We have examined 25.393 samples which
were collected through invasive procedures such as am-
niocentesis (92%) and villocentesis (8%). The almost to-
tality of patients that asked for the analysis of the most
frequent mutations affecting the cystic fibrosis gene did
not have any family history for cystic fibrosis, thus, with
some approximation, the sample can be considered as
random. 
Methods
Analysis Method: DNA extraction and amplification of
the CFTR gene through PCR Multiplex. Amplifications
were performed of exons 2, 3, 7, 9, 10, 11, 13, 17a, 17b,
19, 20, 21 and of introns 1, 3, 4, 5, 8, 10, 11, 12, 14b,
16, 17a, 19. Reverse dot blot hybridization: Innogenet-
ics N.V. Tecnologiepark, 6 Gent-Belgium. The following
mutations have been examined: deltaF508, deltaI507,
1717 -1G-A, G542X, R553X, R560T, W1282X, 3905in-
sT, N1303K, 711+1G-T, 1898-1G-A, 3120+1G-A,
394delTT, G85E, 621+1G-T, R117H, 1078delT, R347P,
R334W, 2183AA -G, 2184delA, 2789 + 5G-A, R1162X,
3659delC, 3849 + 10kbC -T, A455E, S549N, S549R,
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G551D, V520F, 3876delA , F508C, I506V, I507T. In the
case a mutation was identified amongst those examined
we further examined the seuquences through the Italian
Regional Mutation method of Innogenetics: 1259insA,
4016insT, 4382delA, 852del22, D759G, G1244E,
G1349D, I502T, L1065P, R1158X, T338I, S549R(A-C),
991del5, D1152H, 1898+3A-G, R1070Q, R1066H,
R347H, 621+3A-G, E217G+R334Q (Innogenetics N.V.
Tecnologiepark, 6 Gent-Belgium).
Results
The analyses conducted in our samples to identify the
most frequent mutations in the cystic fibrosis gene were
performed with the following commercial kits: Innolipa
CFTR 19+ and Innolipa CFTR 17 (Innogenetics). We
found only 16 relevant mutations amongst the more than
30 mutations examined. As expected, the most frequent
mutation found in our analysis was the ΔF508 mutation,
which resulted in 63,19% of the mutant alleles, followed
in order of frequency by the N1303K mutation (14,26%)
and G542X (6,6%), and then by the other 13 (Table I).
The identification of the any of the mutations examined
in the first level genetic analysis supported the extension
of the analysis to the search of regional mutations,
reaching in some cases up to 54 mutations. The exten-
sion up to the analysis of 54 mutations did not reveal
any additional mutation on top of those found previous-
ly. Also, we performed in few cases an extended analy-
sis that considered up to 200 mutations, however failing
to reveal any additional diagnostic information. In recent
years it has been possible to increment the sensitivity of
the test by including in the analysis deletions of the ex-
amined region, which are frequently associated to the
clinical manidestation of the disease (12, 13), or apply-
ing methods such as DHPLC (Denaturing High Perform-
ance Liquid Cromatography) (14-16).
It is evident that mutations which are different from those
obtained from our analysis must show a very low or non
relevant frequency if compared to that asoociated with
the mutations found in our sample. 
Several studies have been performed throughout the
years on patients that showed the classical symptoms of
Cystic Fibrosis and who were positive to at least one of the
three validated diagnostic tests (17, 18). These tests are
represented by the sweat test, the analysis of the transep-
ithelial electric potential difference across the airway or in-
testinal epithelium (7, 8, 17-25). The genetic analysis is
considered positive when at least two mutations that de-
termine the disease are identified (7, 8, 17-19).
The genetic exams performed on affected patients in
Italy (9-12, 14, 26-28) have revealed a quite consistent
territorial heterogeneity together with a detection rate
that, depending on the method and on the number of
searched mutations, oscillates between 57% (9) and
90% (10-12). Our sample is constituted mostly by pa-
tients who come from the centre-south regions, where-
as the number of samples from the northern regions of
Italy can be considered irrelevant (less than 2%). 
The genetic examinations performed on patients that
manifested symptoms typical of cystic fibrosis and on
samples from different regions of Italy enabled the iden-
tification of up to 90% of the mutations responsible for
the disease (10-12). In our sample we identified 922 het-
erozygous and 9 homozygous affected fetuses. The fre-
quency of heterozygous is 1/27,5 whereas that of the af-
fected homozygous is 1/2821. The most frequent muta-
tion, as expected, is the ΔF508 found in 63,2% of cases.
The ΔF508 is by far the most frequent mutation (51%)
but the incidence concerning the different mutations
found for cystic fibrosis shows a regional variability that
does not allow to easily predict their patterns and fre-
quencies (6, 9-12). In central Italy, for example, the fre-
quency is around 47,4%, in the north around 59,3% and
in the south around 53,4% (9). The ΔF508 mutation
shows always to be the most frequent, nonetheless it al-
so shows a high frequency variability in several coun-
tries where tests have been performed for the genetic
characterization of the disease (5, 9-12, 29-35).
The second mutation, in terms of relative frequency, is
the N1303K mutation showing a value of 14,26%, fol-
lowed by G542X at 6,6%, W1282X at 3,1%, R553X at
2,6%, G85E at 2,4%, R1162X at 1,9%, G551D at 1,3%,
R117H at 1,1%, the other mutations showing a much
lower incidence, inferior to 1% (Table I).
The ten most frequent mutation cover 97,2% of all of the
mutations detected in our sample. This result suggests
that the remaining 20 examined mutations account only
for 2,8% of the mutated chromosomes that we examined. 
Table I - Mutations observed in the sample.
n. %
ΔF508 594 63,2
N1303K 134 14,3
G542X 62 6,6
W1282X 29 3,1
R553X 24 2,6
G85E 23 2,4
R1162X 18 1,9
G551D 12 1,3
R117H 10 1,1
171 7 -1G->T 8 0,9
2184delA 6 0,6
621+1G->T 5 0,5
R347P 5 0,5
R560T 5 0,5
2183-AA->G 3 0,3
2789+5G->A 2 0,2
711 +1G->T 0 0,0
1078delT 0 0,0
R334W 0 0,0
A455E 0 0,0
ΔI507 0 0,0
S549N 0 0,0
1898+1G->A 0 0,0
3659delC 0 0,0
3849+10kb C->T 0 0,0
3905insT 0 0,0
3120+1G->A 0 0,0
S549R 0 0,0
V520F 0 0,0
3876delA 0 0,0
F508C 0 0,0
394delTT 0 0,0
I506V 0 0,0
I507T 0 0,0
TOTAL 940 100,0
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Table II - Composition of the homozygous fetuses.
ΔF508/¢F508 3
ΔF508/G542X 2
ΔF508/W1282X 2
G542X/G542X 2
TOTAL        9
Discussion
On 25393 examined cases (50786 chromosomes), we
have observed a total of 940 mutations which are dis-
tributed in 922 heterozygous and 9 homozygous affect-
ed. Therefore the frequency of the mutations in our sam-
ples is equal to p=0,0185, hence corresponding to a mu-
tation every 54 chromosomes and, given the small pro-
portion of mutations found in the homozygous, approxi-
mately to a carrier every 27,5 individuals.
The 95% confidence interval of the mutation frequency
is comprised between 0,0173 and 0,0197. In other
words we can state that, given a 95% confidence inter-
val in the population sample we can detect a mutation
every 51-58 chromosomes and a carrier (heterozygous)
every 25,9-29,3 individuals.
The results agree fully with the results from previously
cited studies, which have ascertained the frequency of
carriers in the italian population, estimated by neonatal
screening programs to have an incidence between
1/2730 and 1/3170 newborns (7, 8, 17). From these
studies we can calculate a frequency of carriers be-
tween 1/26 and 1/30. Such data suggets that the used
diagnostic methodology probably has a diagnostic sen-
sitivity which is superior to the estimated value of 80%.
In more simple terms, if we hypothesize that the tests
used in the analysis miss out about 20% of mutations,
we would have found approximately a global frequency
of mutations equal to 0,0231, which corresponds to a
mutation every 43 chromosomes and approximately to a
carrier every 22 individuals. The latter frequency ap-
pears by far much too high compared to the results ob-
tained so far on the italian population. There also would
have been some non-identified pathological cases, a
fact that at the moment we do not consider feasible. On
a whole, 1153 fetuses should be carriers for a mutation,
amongst the 1500 identified, in the CFTR gene and 13-
14 should have been the affected homozygous fetuses. 
The sample examined by us is in prefect agreement with
the Hardy-Weimberg equilibrium, that needs not to be
reached since affected patients often show reduced fer-
tility (36, 37). This can be partly explained by the possi-
ble presence of de novo mutations which tend to main-
tain unaltered the allelic frequency. 
Our work has shown the the rate of heterozygosity
(1/27,5) agrees perfectly with that estimated for the ital-
ian population. According to the literature data, which re-
fer to the results obtained by the genetic examination of
patients affected by cystic fibrosis, the rate of heterozy-
gosity obtained by us appears substantially higher than
what predicted. The detection rates of tests used in our
work is generally accepted to be around 80%, that is to
say that, based on the sensitivity of the diagnostic tests
that were used, approximately 20% of the mutated chro-
mosomes should have gone undetected. In practical
terms, we should have found 1153 heterozygous individ-
uals instead of 922, thus provoking an increment in the
number of affected individuals. Such a scenario would
have determined an heterozygosity rate of 1/22 individ-
uals together with a rate of affected individuals of
1/1868, which is actually higher than the rate estimated
by neonatla screening programs. Further studies on
much larger random samples will certainly be useful to
calculate the actual heterozygosity rate. 
Our work can be considered one of the few studies per-
formed on a substantially random and numerous sam-
ple, and, at the moment, the only one in Italy. Our results
perhaps encourages us to hypothesize a correction of
the detection rates of 1st level screening tests used in
our centre and most commonly used for rapid and easi-
ly reproduceable answers. It is evident that a heterozy-
gosity rate of 1/22 does not compare to any of the liter-
ature data. The rate of 1/27,5, found in our sample, ap-
pears to be very close to that estimated for the italian
population. Given the results of our study, it appears fea-
sible that the actual sensitivity of the tests which are
used can be much higher, and moreover a detection
rate around 80% underestimates the true reliability of
the 1st level test. One possibility is that rare or unfre-
quent mutation have an excessive consideration com-
pared to the more frequent ones. Amongst the fifty or
more mutations which have been examined only 16 of
them have been detected at leat once, while the remain-
ing ones were never found in the analysis. 
The results need to be confirmed throughout the years
since the affected individuals can manifest a symptoma-
Figure 1 - Distribution of the cys-
tic fibrosis mutations.
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tology which does not enable to trace back to the dis-
ease some of the clinical manifestations typical of cystic
fibrosis (38-43). 
These results should also encourage new thoughts re-
garding the diagnostic validity of the most frequent pan-
el of mutations amongst the italian population, leading to
the exclusion of never encountered mutations and the
insertion of other more significant mutations. The actual
sensitivity of these tests should be much higher;
nonetheless, in order to define with certainty their diag-
nostic efficacy, we need to proceed in the collection of
data throughout the next few years to confirm or not our
results in this present work provided from the analysis of
more than 25.000 fetuses. 
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